Meiji Yasuda Asset Management Co Ltd. Sells 220 Shares of Humana Inc. (NYSE:HUM)

Meiji Yasuda Asset Management Co Ltd. cut its holdings in shares of Humana Inc. (NYSE:HUM) by 8.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,289 shares of the insurance provider’s stock after selling 220 shares during the period. Meiji Yasuda Asset Management Co Ltd.’s holdings in Humana were worth $581,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in HUM. FPC Investment Advisory Inc. purchased a new position in Humana during the 4th quarter valued at $27,000. Centricity Wealth Management LLC purchased a new stake in shares of Humana in the 4th quarter worth about $30,000. LFA Lugano Financial Advisors SA boosted its stake in shares of Humana by 56.3% during the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 45 shares in the last quarter. OFI Invest Asset Management purchased a new position in shares of Humana during the fourth quarter valued at about $33,000. Finally, Atwood & Palmer Inc. raised its stake in Humana by 64.5% in the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock worth $39,000 after buying an additional 60 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.

Analyst Upgrades and Downgrades

HUM has been the topic of several research reports. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $290.00 price objective on shares of Humana in a research report on Wednesday, February 12th. Truist Financial raised their target price on Humana from $260.00 to $290.00 and gave the company a “hold” rating in a research note on Monday, January 6th. Piper Sandler upped their price target on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 15th. JPMorgan Chase & Co. lowered their price objective on Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research report on Tuesday, February 18th. Finally, Morgan Stanley dropped their target price on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 12th. Eighteen equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, Humana presently has an average rating of “Hold” and an average price target of $285.68.

Humana Stock Performance

HUM stock opened at $270.04 on Friday. The stock’s 50 day simple moving average is $270.51 and its 200 day simple moving average is $274.93. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $406.46. The stock has a market capitalization of $32.59 billion, a PE ratio of 27.14, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57.

Humana (NYSE:HUM) last announced its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. As a group, research analysts forecast that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be issued a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, March 28th. This represents a $3.54 annualized dividend and a dividend yield of 1.31%. Humana’s payout ratio is 35.58%.

Insider Activity at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the sale, the insider now directly owns 8,181 shares in the company, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.37% of the stock is owned by insiders.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.